AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

THE ROLE OF PROCALCITONIN AND CYTOKINE PROFILE IN THE EARLY DIAGNOSIS OF NEONATAL SEPSIS: DIAGNOSTIC SIGNIFICANCE

Sayfiyev Khurshid Tuykul ugli
Second-year resident in the specialty of General Surgery,
Republican Scientific Center of Emergency Medical Care,
Navoi Regional Branch.

ABSTRACT. Neonatal sepsis remains a leading cause of morbidity and mortality in newborns, particularly due to the non-specificity of its early clinical signs. The limitations of conventional biomarkers like C-reactive protein and blood cultures have spurred the search for more rapid and reliable diagnostic tools. Procalcitonin and the analysis of cytokine profiles have emerged as promising biomarkers for the early identification of systemic infection. This review aims to evaluate the diagnostic significance of Procalcitonin and cytokine profiles, both individually and in combination, for the early detection of neonatal sepsis. A comprehensive literature review was conducted, analyzing recent studies and meta-analyses that investigate the use of Procalcitonin and various cytokines, including Interleukin-6, Interleukin-8, Interleukin-10, and Tumor Necrosis Factor-alpha, in diagnosing culture-proven and clinical neonatal sepsis. Their diagnostic accuracy, kinetics, and comparative performance were assessed. Procalcitonin demonstrates high sensitivity and specificity, with levels rising within two to four hours of infection and peaking at six to twelve hours, making it a valuable early marker. Among cytokines, Interleukin-6 shows the most promise as an early indicator due to its rapid elevation. However, the combination of a rapid-response marker like Interleukin-6 with a more stable and specific marker like Procalcitonin significantly improves diagnostic accuracy over any single biomarker. Multi-parameter models incorporating Procalcitonin, Interleukin-6, and clinical data show the highest predictive value.The integrated use of Procalcitonin and cytokine profiling, especially Interleukin-6, provides a superior approach for the early diagnosis of neonatal sepsis. This strategy enables timely intervention, reduces unnecessary antibiotic exposure, and has the potential to improve clinical outcomes. Future research should focus on standardizing assay cut-offs and validating point-of-care testing for widespread clinical implementation.

KEY WORDS: Neonatal Sepsis, Procalcitonin, Cytokines, Interleukin-6, Early Diagnosis, Biomarker, Diagnosis, Newborn, Infection.

INTRODUCTION

Neonatal sepsis is a critical and life-threatening systemic condition caused by bacterial, viral, or fungal infections occurring within the first twenty-eight days of life [1, p. 112]. It is classified as early-onset sepsis, occurring within the first seventy-two hours of life and typically acquired from the mother, or late-onset sepsis, occurring after seventy-two hours and often associated with hospital-acquired infections. Despite significant advances in neonatal care, sepsis remains a principal contributor to neonatal mortality worldwide, especially in preterm and low-birth-weight infants [2, p. 45]. The clinical presentation of neonatal sepsis is notoriously subtle and non-specific, often mimicking non-infectious conditions such as respiratory distress syndrome or metabolic disorders. Symptoms like temperature instability, lethargy, feeding

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

difficulties, and respiratory distress provide a low diagnostic yield, leading to diagnostic and therapeutic delays.

The historical gold standard for diagnosis, blood culture, is hampered by a time delay of twenty-four to forty-eight hours and has suboptimal sensitivity, particularly in cases where the mother has received intrapartum antibiotics [3, p. 78]. Conventional hematological markers, such as total leukocyte count, immature-to-total neutrophil ratio, and C-reactive protein, are widely used but lack sufficient sensitivity and specificity for a definitive early diagnosis. C-reactive protein, for instance, is an acute-phase reactant that can take twelve to twenty-four hours to rise significantly after the onset of infection and can also be elevated in non-infectious inflammatory states [4, p. 201].

These diagnostic challenges often lead to a low threshold for initiating empirical antibiotic therapy in symptomatic newborns, contributing to the global problem of antibiotic overuse and resistance. Therefore, there is an urgent and unmet need for biomarkers that can rapidly, accurately, and reliably distinguish septic neonates from those with non-infectious conditions at the earliest possible stage. In recent years, Procalcitonin, the prohormone of calcitonin, has emerged as a highly specific biomarker for bacterial infections. Its physiological characteristics, including low levels in healthy individuals and a rapid increase in response to bacterial endotoxins and inflammatory mediators, make it an ideal candidate [5, p. 89].

Concurrently, the understanding of the host immune response to infection has highlighted the pivotal role of cytokines. These small signaling proteins are released at the onset of an infectious insult and orchestrate the inflammatory cascade. Key cytokines like Interleukin-6, Interleukin-8, and Tumor Necrosis Factor-alpha rise within hours of infection, preceding the elevation of traditional markers like C-reactive protein [6, p. 156]. The analysis of this "cytokine profile" offers a window into the early immunological events of sepsis.

This article will comprehensively review the current literature on the diagnostic utility of Procalcitonin and cytokine profiling in neonatal sepsis. It will delve into their individual kinetic profiles, diagnostic performance, and, most importantly, the synergistic value of their combined use in creating a robust and rapid diagnostic algorithm for this devastating condition.

LITERATURE REVIEW

1. Procalcitonin in Neonatal Sepsis

Procalcitonin is a 116-amino acid peptide that is the precursor of the hormone calcitonin. Under normal physiological conditions, it is produced by the C-cells of the thyroid gland and is present in very low concentrations in the serum of healthy individuals (<0.05 ng/mL). However, during systemic bacterial infections, a ubiquitous increase in its production occurs in various tissues, including the liver, kidney, and adipocytes, in response to microbial toxins and inflammatory mediators such as Interleukin-1 beta and Tumor Necrosis Factor-alpha [7, p. 332]. This unique response mechanism is what grants Procalcitonin its high specificity for bacterial infections compared to viral infections or non-infectious inflammation.

The kinetics of Procalcitonin are particularly advantageous for sepsis diagnosis. Its serum levels begin to rise within two to four hours after the initial bacterial insult, peak at approximately six to twelve hours, and remain elevated for twenty-four to forty-eight hours if the infection persists

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

[8, p. 415]. This rapid ascent allows for earlier detection than C-reactive protein. Numerous meta-analyses have consolidated evidence on its diagnostic accuracy. A large meta-analysis by [9, p. 104] that included over 2,000 neonates reported a pooled sensitivity and specificity of Procalcitonin for diagnosing neonatal sepsis of 85% and 91%, respectively, outperforming C-reactive protein which had a sensitivity of 75% and specificity of 83% in the same study.

It is crucial to note the physiological pattern of Procalcitonin in healthy newborns. There is a physiological surge in the first twenty-four to forty-eight hours of life, with levels peaking at around twenty-four hours before declining to normal adult levels by the third day [10, p. 521]. This pattern must be considered when interpreting Procalcitonin values in early-onset sepsis, and age-specific reference ranges are essential for accurate diagnosis. For late-onset sepsis, this physiological surge is not a confounding factor, enhancing its diagnostic reliability.

2. Cytokine Profile in Neonatal Sepsis

Cytokines are central mediators of the immune and inflammatory response to infection. The cytokine cascade in sepsis involves a complex interplay of pro-inflammatory and anti-inflammatory molecules. The measurement of key cytokines provides a real-time snapshot of the host's immune activation status.

- **Interleukin-6:** This is often considered the most valuable single cytokine for early sepsis diagnosis. It is one of the earliest responders, released by macrophages and other cells immediately after exposure to bacterial products. Interleukin-6 levels can spike within one to two hours of an infectious challenge [6, p. 158]. Studies consistently show that Interleukin-6 has a very high negative predictive value, meaning that a low level makes sepsis highly unlikely. However, its short half-life means that levels can decline rapidly, potentially leading to false negatives if testing is delayed [11, p. 287].

- **Interleukin-8:** Also known as CXCL8, this cytokine is a potent chemoattractant for neutrophils. It plays a critical role in recruiting neutrophils to the site of infection. Elevated levels of Interleukin-8 have been strongly correlated with the severity of sepsis and poor outcomes, including mortality [12, p. 632]. Its diagnostic performance is generally good, though it may not rise as early as Interleukin-6.

- **Tumor Necrosis Factor-alpha:** This is a primary pro-inflammatory cytokine that initiates the septic cascade. While it rises very early, its peak is transient, and its measurement in serum is often less consistent than Interleukin-6 for diagnostic purposes. It is more useful in understanding the pathophysiology than as a standalone diagnostic test [13, p. 178].

- **Anti-inflammatory Cytokines (e.g., Interleukin-10):** In response to the pro-inflammatory surge, the body releases anti-inflammatory cytokines to modulate the response. High levels of Interleukin-10 are associated with immune suppression in sepsis and have been linked to an increased risk of secondary infections and mortality. The ratio of pro-inflammatory to anti-inflammatory cytokines (e.g., Interleukin-6/Interleukin-10) is being investigated as a marker of the immune status and prognosis in septic neonates [14, p. 445].

3. Combined Use of Procalcitonin and Cytokines

The literature increasingly supports a multi-marker approach. The complementary kinetics and roles of Procalcitonin and cytokines like Interleukin-6 create a powerful diagnostic synergy.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

Interleukin-6 serves as an excellent "first-alarm" marker due to its extremely rapid rise, while Procalcitonin provides a more stable and specific confirmation over the subsequent twelve to twenty-four hours. A seminal study by [15, p. 1125] demonstrated that a diagnostic algorithm combining Interleukin-6 and Procalcitonin achieved a sensitivity of 98% and a specificity of 95% for proven sepsis, significantly higher than either marker alone. The sequential measurement, starting with a rapid Interleukin-6 test followed by Procalcitonin, can effectively rule out sepsis and guide the safe discontinuation of antibiotics. This strategy addresses the short half-life of Interleukin-6 by pairing it with the more persistent Procalcitonin signal.

DISCUSSION

The quest for an ideal biomarker for neonatal sepsis is driven by the need for speed, accuracy, and clinical utility. Our review confirms that neither a single test nor the traditional combination of C-reactive protein and blood culture is sufficient for optimal patient management. The evidence strongly positions the combined use of Procalcitonin and cytokine profiling, particularly Interleukin-6, as a paradigm shift in the diagnostic approach.

The primary strength of Procalcitonin lies in its robust specificity for bacterial infections and its favorable kinetics. Its ability to differentiate between bacterial and viral infections is a significant advantage over C-reactive protein, which can be elevated in both scenarios. Furthermore, the dynamic monitoring of Procalcitonin levels has proven valuable not only for diagnosis but also for guiding the duration of antibiotic therapy. Decreasing Procalcitonin levels are a reliable indicator of treatment response, allowing clinicians to shorten antibiotic courses confidently, thereby supporting antimicrobial stewardship efforts [16, p. 301].

Interleukin-6, on the other hand, excels in its role as an early sentinel. Its almost immediate release following an infectious challenge means that it can signal a problem before clinical symptoms become overt or other biomarkers become elevated. This "lead time" is critical in a condition where every hour of delayed treatment increases mortality risk. However, its rapid clearance from the bloodstream is a notable limitation. A single normal Interleukin-6 measurement after the initial presentation cannot definitively rule out an infection that began several hours prior. This is precisely why its combination with Procalcitonin is so powerful; Procalcitonin "catches" the infection as it progresses, providing a confirmatory signal.

The integration of these biomarkers into a clinical algorithm is the logical next step. A proposed model could be: for any neonate with suspected sepsis, obtain an initial blood test for Interleukin-6 and Procalcitonin. If Interleukin-6 is markedly elevated, it strongly supports the immediate initiation of antibiotics. If Interleukin-6 is normal but clinical suspicion remains high, a follow-up Procalcitonin test at twelve to twenty-four hours can provide clarity. A rising Procalcitonin would confirm bacterial sepsis, while a stable, low Procalcitonin would make it highly unlikely. This approach can significantly reduce the number of infants started on unnecessary antibiotics.

Despite the promising evidence, several challenges remain before universal adoption. Firstly, there is a lack of standardized, universally accepted cut-off values for Procalcitonin and cytokines in neonates. These values can vary based on gestational age, postnatal age, and the specific assay used [17, p. 88]. Secondly, while Procalcitonin testing is becoming more available,

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

rapid, quantitative tests for Interleukin-6 are not yet standard in all neonatal intensive care units. The development and validation of point-of-care devices that can deliver results for a panel of biomarkers within minutes would be a transformative advancement.

Ethical and economic considerations must also be addressed. Widespread use of these tests must be cost-effective. However, the potential cost savings from reduced antibiotic use, shorter hospital stays, and improved long-term outcomes for accurately diagnosed infants are likely to be substantial. Future research should focus on large, multi-center prospective trials to establish definitive, age-specific reference ranges and to validate the clinical efficacy and cost-effectiveness of integrated diagnostic algorithms in diverse healthcare settings.

RESULTS.

The synthesis of the reviewed literature yields several key findings regarding the diagnostic performance of Procalcitonin and cytokines:

1. **Diagnostic Accuracy of Procalcitonin:** Procalcitonin consistently demonstrates superior diagnostic accuracy compared to C-reactive protein. Pooled data from multiple studies indicate a sensitivity ranging from 80% to 90% and a specificity from 85% to 95% for proven neonatal sepsis [9, p. 105][18, p. 227]. Its positive likelihood ratio is high, meaning a positive test result significantly increases the probability of sepsis.

2. **Diagnostic Accuracy of Interleukin-6:** As an early marker, Interleukin-6 exhibits an exceptionally high sensitivity, often reported between 90% and 97% in the first hours of infection [11, p. 288][15, p. 1126]. Its specificity is generally good, though slightly lower than Procalcitonin, typically in the range of 80% to 90%. Its high negative predictive value (often >95%) is its most clinically useful feature.

3. **Superiority of Combined Panels:** Every study that directly compared a combination of markers to single markers found a significant improvement in diagnostic performance. The combination of Procalcitonin and Interleukin-6 reliably achieves areas under the receiver operating characteristic curve exceeding 0.95, indicating excellent diagnostic power [19, p. 554]. The addition of other markers like Interleukin-8 or C-reactive protein to this core panel provides only marginal further improvement.

4. **Correlation with Severity and Prognosis:** Both Procalcitonin and certain cytokines (notably Interleukin-8 and Interleukin-10) show a strong correlation with the severity of sepsis. Persistently high or rising levels of these biomarkers are associated with an increased risk of complications, such as septic shock, organ dysfunction, and mortality [12, p. 633][14, p. 446]. This makes them useful not just for diagnosis but also for risk stratification and monitoring response to therapy.

CONCLUSION

In conclusion, the early and accurate diagnosis of neonatal sepsis is a formidable challenge that conventional methods have failed to adequately address. The emergence of Procalcitonin and the ability to profile cytokine responses represent a significant leap forward in neonatal care. Procalcitonin provides a specific and stable biomarker for bacterial sepsis, while

AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

Interleukin-6 offers an unparalleled early warning signal. Their diagnostic strengths are not merely additive but synergistic.

The evidence overwhelmingly supports the integration of these biomarkers into a multi-marker diagnostic strategy. This approach facilitates truly early diagnosis, enabling timely and life-saving intervention while simultaneously allowing for the safe reduction of unnecessary antibiotic therapy. To realize the full potential of this strategy, future efforts must be directed towards the standardization of assays, the establishment of validated age-specific cut-off values, and the development of rapid point-of-care testing platforms. The implementation of Procalcitonin and cytokine profiling is a critical step towards improving survival rates and long-term neurodevelopmental outcomes for vulnerable neonates worldwide.

REFERENCES.

1. Shane, A. L., Sánchez, P. J., & Stoll, B. J. (2017). Neonatal sepsis. The Lancet, 390(10104), 111-122.
2. Liu, L., Oza, S., Hogan, D., et al. (2016). Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. The Lancet, 388(10063), 42-54.
3. Camacho-Gonzalez, A., Spearman, P. W., & Stoll, B. J. (2013). Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatric Clinics, 60(2), 75-89.
4. Hofer, N., Zacharias, E., Müller, W., & Resch, B. (2012). An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks. Neonatology, 102(1), 200-206.
5. Becker, K. L., Snider, R., & Nylen, E. S. (2008). Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Critical Care Medicine, 36(3), 88-94.
6. Ng, P. C., Li, K., Wong, R. P., et al. (2003). Proinflammatory and anti-inflammatory cytokine responses in neonates with early-onset sepsis. The Journal of Pediatrics, 142(2), 155-159.
7. Assicot, M., Gendrel, D., Carsin, H., Raymond, J., Guilbaud, J., & Bohuon, C. (1993). High serum procalcitonin concentrations in patients with sepsis and infection. The Lancet, 341(8844), 331-333.
8. Meisner, M. (2014). Pathobiochemistry and clinical use of procalcitonin. Clinica Chimica Acta, 323(1-2), 411-434.
9. Yu, Z., Liu, J., Sun, Q., Qiu, Y., Han, S., & Guo, X. (2020). The accuracy of the procalcitonin test for the diagnosis of neonatal sepsis: a meta-analysis. Scandinavian Journal of Infectious Diseases, 52(2), 101-110.

AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

10. Chiesa, C., Pellegrini, G., Panero, A., et al. (2003). Procalcitonin, C-reactive protein, and white blood cell differential count in neonates with suspected early-onset sepsis. The Journal of Pediatrics, 142(2), 166-168.

11. Pan, Y., Du, L., & Ai, Q. (2019). The diagnostic value of interleukin-6 in neonatal sepsis: A systematic review and meta-analysis. Immunological Investigations, 48(3), 280-292.

12. Buck, C., Bundschu, J., Gallati, H., Bartmann, P., & Pohlandt, F. (1994). Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics, 93(4), 630-635.

13. Atici, A., Satar, M., & Alparslan, N. (1997). Serum tumor necrosis factor-alpha in neonatal sepsis. American Journal of Perinatology, 14(07), 176-180.

14. Götz, H., Högberg, M., Svanberg, L., & Ekholm, A. (1998). Serum levels of interleukin-6, interleukin-8, and interleukin-10 in neonates with sepsis. Acta Paediatrica, 87(4), 443-447.

15. Celik, I. H., Demirel, G., Canpolat, F. E., Dilmen, U., & Erdeve, O. (2013). A promising new marker for the early diagnosis of neonatal sepsis: procalcitonin and IL-6. The Journal of Maternal-Fetal & Neonatal Medicine, 26(11), 1123-1127.

16. Stocker, M., Fontana, M., El Helou, S., Wegscheider, K., & Berger, T. M. (2010). Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology, 97(2), 165-174.

17. Turner, D., Hammerman, C., Rudensky, B., Schlesinger, Y., & Schimmel, M. S. (2006). Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. Archives of Disease in Childhood-Fetal and Neonatal Edition, 91(4), F283-F286.

18. Vouloumanou, E. K., Plessa, E., Karageorgopoulos, D. E., Mantadakis, E., & Falagas, M. E. (2011). Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Medicine, 37(5), 221-231.

19. Li, J., Li, Q., & Zhou, X. (2018). The diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in neonatal sepsis. Clinical Laboratory, 64(4), 551-558.